Twist Bioscience/$TWST
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Twist Bioscience
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
- Ticker
- $TWST
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 979
- Headquarters
- South San Francisco, United States
- Website
- www.twistbioscience.com
Twist Bioscience Metrics
BasicAdvanced
$7.6B
-
-$2.23
2.22
-
Price and volume
Market cap
$7.6B
Beta
2.22
52-week high
$219.71
52-week low
$23.30
Average daily volume
2.9M
Financial strength
Current ratio
2.672
Quick ratio
1.928
Long term debt to equity
0.224
Total debt to equity
0.244
Profitability
EBITDA (TTM)
-115.282
Gross margin (TTM)
51.97%
Net profit margin (TTM)
-31.66%
Operating margin (TTM)
-31.91%
Effective tax rate (TTM)
-0.64%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-13.09%
Return on equity (TTM)
-29.59%
Valuation
Price to revenue (TTM)
17.177
Price to book
16.98
Price to tangible book (TTM)
16.98
Price to free cash flow (TTM)
-75.51
Free cash flow yield (TTM)
-1.32%
Free cash flow per share (TTM)
-1.6
Growth
Revenue change (TTM)
19.19%
Earnings per share change (TTM)
54.97%
3-year revenue growth (CAGR)
22.40%
3-year earnings per share growth (CAGR)
-15.50%
What the Analysts think about Twist Bioscience
Analyst ratings (Buy, Hold, Sell) for Twist Bioscience stock.
Analyst projections of the future price of Twist Bioscience stock.
Bulls say / Bears say
Third-quarter revenue rose 23% year on year, marking 14 consecutive quarters of sequential growth, and Twist raised its fiscal 2026 revenue outlook to $456–457 million. Gross margin also improved sequentially to 52.8%, supporting the case that growth is starting to improve operating leverage. (SEC)
Twist launched MRD Express, custom panels for cancer research that can include up to 10,000 probes and have a turnaround time starting within one day. Faster production could help it win work as researchers develop molecular-residual-disease tests. (Twist Bioscience)
The Lilly TuneLab agreement makes Twist a provider of antibody-characterisation services for users of Lilly’s AI drug-discovery platform. This gives Twist a route to serve researchers linking AI predictions with laboratory data, though the announcement does not establish the scale of future sales. (Twist Bioscience)
Twist remained loss-making: it reported a $35.1 million net loss in the third quarter and an adjusted EBITDA loss of $11.3 million, while quarterly selling, general and administrative costs rose to $80.7 million from $63.4 million a year earlier. Revenue growth has therefore not yet translated into lower underlying losses. (SEC)
Twist’s August prospectus set out a large common-share offering to fund research, manufacturing expansion and general corporate needs. Raising equity can extend its funding runway, but it also dilutes existing shareholders and highlights that growth still requires external capital. (SEC)
The top 10 customers generated 48% of NGS Applications revenue in the third quarter, according to the earnings-call figures. Reliance on a small group of accounts leaves this segment exposed if a major customer reduces orders or changes supplier. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
Twist Bioscience Financial Performance
Revenues and expenses
Twist Bioscience Earnings Performance
Company profitability
Upcoming events
No upcoming events
Twist Bioscience News
AllArticlesVideos
Funds containing Twist Bioscience
AllUSDEURGBP
Fund name | Fund size | $TWST weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $123M | 7.41% |
ARK Genomic Revolution£ARCG | $123M | 7.41% |
ARK Innovation£ARCK | $325M | 3.57% |
ARK Innovation€ARXK | $325M | 3.57% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.68% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.